The MRI Features and Prognosis of Gliomas Associated With IDH1 Mutation: A Single Center Study in Southwest China

• Published in: Frontiers in oncology Vol. 10; p. 852
• Main Authors: Shen, Guiquan, Wang, Rujia, Gao, Bo, Zhang, Zhongwen, Wu, Guipeng, Pope, Whitney
• Format: Journal Article
• Language: English
• Published: Frontiers Media S.A 02-06-2020
• Subjects: glioma; IDH1 mutation; MRI features; Oncology; overall survival; prognosis
• ISSN: 2234-943X; 2234-943X
• DOI: 10.3389/fonc.2020.00852

Purpose:
To investigate the associations of MRI radiological features and prognosis of glioma with the status of isocitrate dehydrogenase 1 (IDH1).
Material and Methods:
A total of 116 patients with gliomas were retrospectively recruited from January 2013 to December 2015. All patients were undergone routine MRI (T1WI, T2WI, T2-FLAIR) scanning and contrast-enhanced MRI T1WI before surgery. The following imaging features were included: tumor location, diameter, the pattern of growth, boundary, the degree of enhancement, mass effect, edema, cross the middle line, under the ependyma. χ
2
and Fisher's exact probability tests were used to determine the significance of associations between MRI features and IDH1 mutation of glioma. The survival distributions were estimated using Kaplan-Meier compared by Log-rank test. Univariate and multivariate analyses were performed using Cox regression.
Results:
Gliomas with IDH1 mutant were significantly more likely to exhibit homogeneous signal intensity (
p
= 0.009) on non-contrast MRI protocols and less contrast enhancement (
p
= 0.000) on contrast enhanced T1WI. IDH1 mutant type glioma was more inclined to cross the midline to invade contralateral hemisphere (
p
= 0.001). The overall survival between IDH1 mutated and wild type glioma were significantly different (
p
= 0.000), age ≤ 40 (
p
= 0.003), KPS scores > 80 before operation (
p
= 0.000) and low grade glioma (
p
= 0.000).
Conclusions:
Our results suggest IDH1 mutant in gliomas is more likely to exhibit homogeneous signal intensity, less contrast enhancement and more inclined to cross the midline. Patients with IDH1 mutated, age ≤ 40, KPS scores > 80 before operation and low-grade glioma may have a longer life and better prognosis.